Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
41.82
-0.78 (-1.83%)
At close: Aug 13, 2026, 4:00 PM EDT
42.48
+0.66 (1.58%)
Pre-market: Aug 14, 2026, 8:00 AM EDT
Company Description
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases.
It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren’s disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.
The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Immunovant, Inc.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 315 |
| CEO | Eric Venker |
Contact Details
Address: 1000 Park Forty Plaza, Suite 210 Durham, North Carolina 27713 United States | |
| Phone | 917 410 3120 |
| Website | immunovant.com |
Stock Details
| Ticker Symbol | IMVT |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 1764013 |
| CUSIP Number | 45258J102 |
| ISIN Number | US45258J1025 |
| Employer ID | 83-2771572 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Eric Venker M.D., Pharm.D. | Chief Executive Officer and Director |
| Dr. Frank M. Torti M.B.A., M.D. | Executive Chairperson of the Board |
| Tiago M. Girao CPA | Chief Financial Officer |
| Melanie Gloria B.S.N. | Chief Operating Officer |
| Dr. Jay S. Stout M.S., Ph.D. | Chief Technology Officer |
| Christopher A. Van Tuyl Esq., J.D. | Chief Legal Officer and Corporate Secretary |
| Christine Blodgett | Senior Vice President of Human Resources |
| Becky Merlina | Senior Vice President and Global Head of Quality |
| Yan Zheng M.S., Ph.D. | Senior Vice President of Biostatistics, Programming and Data Management |
| Sheetal Patel M.B.A., M.D., M.S. | Senior Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 6, 2026 | 10-Q | Quarterly Report |
| Aug 6, 2026 | 8-K | Current Report |
| Jul 22, 2026 | ARS | Filing |
| Jul 22, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 22, 2026 | DEF 14A | Other definitive proxy statements |
| Jun 26, 2026 | 144 | Filing |
| Jun 26, 2026 | 144 | Filing |
| Jun 26, 2026 | 144 | Filing |
| Jun 26, 2026 | 144 | Filing |
| Jun 15, 2026 | 144 | Filing |